Company overview
Abcam is a life sciences company established in 1998 that provides highly validated antibodies, assays, proteins, and research reagents to support drug discovery, diagnostics, and basic research. The company serves 750,000 researchers across 130+ countries and offers full-cycle support from antibody identification and development through validation, pre-clinical selection, and commercialization. Abcam specializes in delivering well-characterized proteins and reagents targeting critical biological pathways in cancer, neurological disorders, infectious diseases, and metabolic disorders. Now operating as part of Danaher's Life Sciences segment, Abcam continues to provide expert scientific support and data-driven expertise in antibody discovery and production.
Industry categories: Life Science Reagents, Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Antibodies, Assays & Research Reagents for Drug Discovery include Reagent, Assay, Diagnostic — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.abcam.com/en-us/about
- Categories
- Life Science Reagents, Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- antibodies, research reagents, drug discovery, assays, recombinant proteins, life sciences, diagnostics
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What products and services does Abcam offer for drug discovery?
- Abcam provides antibodies, assays, proteins, lysates, tissue slides, and other research reagents. The company offers full-cycle support including antibody identification and development, validation, pre-clinical selection, licensing, and commercialization. Abcam also delivers recombinant protein engineering, synthesis, and production services at scale.
- What is Abcam's geographic reach and customer base?
- Abcam serves approximately 750,000 researchers across more than 130 countries. The company operates globally and maintains university-wide agreements with research institutions for antibody-based research products and life sciences reagents.
- What recent initiatives is Abcam undertaking in AI-driven drug discovery?
- Abcam joined the Innovative Health Initiative LIGAND-AI project, a public-private partnership led by the Structural Genomics Consortium and Pfizer with a budget exceeding €60 million. Through this five-year collaboration across nine countries, Abcam contributes expertise in recombinant protein engineering and production to generate high-quality protein-ligand datasets for training AI models to predict candidate molecules as suitable binders for thousands of human proteins.
Related editorial coverage
- Drug Discovery USA 2026: What to Expect
- The Market for Monoclonal Antibodies: Trends, Challenges, and Opportunities in 2024
- ASCO ‘26: Bispecifics, ADCs, and the RAS Revolution Reshape Oncology
- Top Biotech Gainers: CODX, NRXP, NVAX - Clinical Trials Update
- Lunai Bioworks and BrainStorm Therapeutics Launch AI Collaboration for Parkinson's and Rare Epilepsy
- Verge Rebrands AI Drug Discovery After Trial Setback
Explore lab tools and QA/QC resources for R&D teams.
